HCPCS Level IIdrugActive
J2354
Octreotide inj, non-depot
BETOS: O1E
Effective: 2004-01-01
Referenced in 2 policies
Description
Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Sandostatin
Manufacturer
Novartis Pharmaceuticals Corporation
HCPCS Dosage
25 MCG
Billing Units
2.0000
33
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.